Abstract

Obesity and type 2 diabetes are heterogeneous, network-level disorders arising from the interplay of genetic 
variation, epigenetic remodeling, environmental exposures, and metabolic rewiring across adipose tissue, liver, 
skeletal muscle, gut, and pancreatic islets. Precision therapy requires not only stratifying patients by molecular 
drivers but also delivering interventions to the right tissue compartments with timing that reflects circadian 
and behavioral rhythms. Nanotechnology offers an enabling bridge between molecular diagnosis and actionable, 
patient-tailored treatment. Engineered nanoparticles like lipidic, polymeric, inorganic, or hybrid, can 
encapsulate diverse payloads, including small molecules, peptides, nucleic acids, and genome or epigenome 
editors, while incorporating ligands that target organ- and cell-specific receptors or microenvironmental cues. 
Meanwhile, minimally invasive diagnostics that harness circulating exosomes, cell-free nucleic acids, and 
metabolomic signatures can guide endotype discovery and longitudinal monitoring. This review outlines a 
framework for nanotechnology-enabled personalized medicine in obesity and type 2 diabetes that integrates 
genomics, epigenomics, and metabolomics with smart delivery systems. We examine patient stratification using 
polygenic risk and epigenetic clocks, design rules for targeted and stimuli-responsive nanocarriers, and 
strategies for aligning pharmacokinetics with metabolic states. Preclinical and emerging clinical evidence 
indicate that matching payload and carrier to molecular endotypes can amplify efficacy while reducing systemic 
exposure. We further discuss safety, manufacturability, regulatory science, and health equity considerations that 
determine feasibility at scale. By coupling molecular insight to programmable delivery, nanomedicine can move 
care beyond one-size-fits-all glycemic control toward durable network reprogramming tailored to each patient’s 
biological context.